Trials / Recruiting
RecruitingNCT06752863
Labetalol Infusion and Dexmedetomidine Infusion in Hypotensive Anesthesia
Comparative Study of Labetalol Infusion Versus Dexmedetomidine Infusion in Hypotensive Anesthesia in Ear, Nose and Throat Surgeries
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Ain Shams University · Academic / Other
- Sex
- All
- Age
- 20 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
this study aims to compare between the role of Labetalol infusion versus Dexmedetomidine infusion in hypotensive anesthesia in Ear, Nose and Throat surgeries.
Detailed description
Hypotensive anaesthesia is the deliberate lowering of a patient's blood pressure during surgery. It is necessary during ear, nose and throat surgery for drying surgical field, ease in operation procedure and shortening of the duration of surgery. Labetalol is a unique parenteral anti-hypertensive drug that has selective α1 and non- selective β adrenergic antagonist effects. In humans, the β to α blocking potency ratio is 7: 1 for IV labetalol. Dexmedetomidine is highly selective alpha2 adrenergic agonist having several beneficial actions during the perioperative period. Activation of alpha2 adrenergic receptors in the brain and spinal cord inhibits neuronal firing causing hypotension and bradycardia. This study was designed to compare between the role of Labetalol infusion versus Dexmedetomidine infusion in hypotensive anesthesia in Ear, Nose and Throat surgeries.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hypotensive anesthesia in ear, nose and throat surgeries using labetalol and dexmedetomidine infusions | The study compares the role of Labetalol infusion versus Dexmedetomidine infusion in hypotensive anesthesia in patients having ear, nose and throat surgeries |
Timeline
- Start date
- 2024-11-27
- Primary completion
- 2025-10-01
- Completion
- 2025-12-01
- First posted
- 2024-12-31
- Last updated
- 2024-12-31
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT06752863. Inclusion in this directory is not an endorsement.